跳到主要內容

Sablich Kim 的 Form 4 申報

Jazz Pharmaceuticals plc(JAZZ),2023/3/10 申報

申報編號
0001765581-23-000036
申報時間
2023/3/10
交易日
2023/3/8
申報延遲
2 天
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $42.1 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Sablich KimCIK 0001758790高階主管(EVP, GM of U.S., Commercial Ma)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2023/3/8Ordinary SharesS賣出處分−1,752$139.42F2−$244,263.8431,821直接
2023/3/8Ordinary SharesS賣出處分−1,261$140.19F3−$176,779.5930,560直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F2

Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

表 I 有 1 筆交易的價格引用這則附註。

F3

Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)